Modulation of ABCG2 Transporter Activity by Ko143 Derivatives
ACS Chemical Biology · 15.11.2024 · 19 (11) · 2304-2313
DOI: 10.1021/acschembio.4c00353 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 24.10.2024. Verfasst von Qin Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biophysics, Department of Biology, ETH Zurich, Zurich 8093, Switzerland. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Neoplasm Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
ABCG2 is a multidrug transporter that protects tissues from xenobiotics, affects drug pharmacokinetics, and contributes to multidrug resistance of cancer cells. Here, we present tetracyclic fumitremorgin C analog Ko143 derivatives, evaluate their in vitro modulation of purified ABCG2, and report four high-resolution cryo-EM structures and computational analyses to elucidate their interactions with ABCG2. We found that Ko143 derivatives that are based on a ring-opened scaffold no longer inhibit ABCG2-mediated transport activity. In contrast, closed-ring, tetracyclic analogs were highly potent inhibitors. Strikingly, the least potent of these compounds, MZ82, bound deeper into the central ABCG2 cavity than the other inhibitors and it led to partial closure of the transmembrane domains and increased flexibility of the nucleotide-binding domains. Minor structural modifications can thus convert a potent inhibitor into a compound that induces conformational changes in ABCG2 similar to those observed during binding of a substrate. Molecular dynamics simulations and free energy binding calculations further supported the correlation between reduced potency and distinct binding pose of the compounds. We introduce the highly potent inhibitor AZ99 that may exhibit improved in vivo stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Biology and Biophysics, Department of Biology, ETH Zurich, Zurich 8093, Switzerland.
- Theoretical and Computational Biophysics Group, NIH Center for Macromolecular Modeling and Visualization, Beckman Institute for Advanced Science and Technology, Department of Biochemistry, and Center for Biophysics and…
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland.
- Laboratory of Biological Electron Microscopy, Institute of Physics, SB, EPFL, Lausanne 1015, Switzerland.
ORCID-Profile: Rose Bang-Soerensen, Po-Chao Wen, Karl-Heinz Altmann, Emad Tajkhorshid, Kaspar P Locher
Förderung
- NIGMS NIH HHS
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
Zitieren
APA
Yu, Q., Dehghani-Ghahnaviyeh, S., Rasouli, A., Sadurni, A., Kowal, J., Bang-Soerensen, R., Wen, P. C., Tinzl-Zechner, M., Irobalieva, R. N., Ni, D., Stahlberg, H., Altmann, K. H., Tajkhorshid, E., & Locher, K. P. (2024). Modulation of ABCG2 Transporter Activity by Ko143 Derivatives. ACS Chemical Biology, 19(11), 2304-2313. https://doi.org/10.1021/acschembio.4c00353
Vancouver
Yu Q, Dehghani-Ghahnaviyeh S, Rasouli A, Sadurni A, Kowal J, Bang-Soerensen R, et al. Modulation of ABCG2 Transporter Activity by Ko143 Derivatives. ACS Chemical Biology. 2024;19(11):2304-2313. doi:10.1021/acschembio.4c00353
BibTeX
@article{Yu2024,
author = {Yu, Qin and Dehghani-Ghahnaviyeh, Sepehr and Rasouli, Ali and Sadurni, Anna and Kowal, Julia and Bang-Soerensen, Rose and Wen, Po-Chao and Tinzl-Zechner, Melanie and Irobalieva, Rossitza N and Ni, Dongchun and Stahlberg, Henning and Altmann, Karl-Heinz and Tajkhorshid, Emad and Locher, Kaspar P},
title = {Modulation of ABCG2 Transporter Activity by Ko143 Derivatives},
journal = {ACS Chemical Biology},
year = {2024},
volume = {19},
number = {11},
pages = {2304--2313},
doi = {10.1021/acschembio.4c00353}
}
EUVIMED